Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Researchers documented a six per cent to nine per cent decline in grocery spending within the first six months of the GLP-1 drug use driven by “significantly larger” decreases in purchases of calorie-dense processed items, including an 11 per cent decline in savoury snacks.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau,

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection that promised to transform the lives of those struggling with obesity. The click-baity headlines surrounding Ozempic,